Member Info for rhubarbmk2

Hokkaido is a certain type of drug that needed to be better formulated and IP protected to make sure that it was worth testing. This took a lot more effort than expected. It now is. This is the proper thing to do. At least if it works, they know that the commercial drug will.

Barcelona is further ahead, as the testing material was in a more "good-to-go" format, so I can't see a delay with this one.

BC201 has produced striking results (see patent), which will now have been repeated for anti/inflammatory/sepsis indications. This will be published soon, and then likely marketed.

VAL301 is potentially on the cusp of becoming a brand-new drug. May as well call it "VLX001". Get rid if the legacy baggage.

That's potentially FOUR drugs in the pipeline with 18/19 year patents.

I'm calling that one of these will be a "blockbuster". 400M milestone package.

The BOD have gotten no credit for the above, and credit is due.

I actually genuinely forgot about CLX001. Wonder drug to date. So that's FIVE potential pre-IND drugs.

I'll call it now. Best to sell up if you don't like them, but I think that 2023 will be transformational.

But don't let that get on the way of a good moan about Ken and Patrick, or a placing that Porky is trying to force.

Haven't actually lost confidence in 201. I'd like to know more, but it is what it is. And do you honestly think that the BOD would take so much stick over it, and risk their own reputations, if it was a dead duck? There's no logic to that. They could drop it now, and it would barely ripple.

Not that it matters, because KCTNBC work to date is worth 10p on its own; listing is worth 3-4p.

So although we are not trading below cash, this is the asset equivalent.

The important thing in these scenarios is to keep a cool head.

If you don't need to sell out in the next few weeks, the SP is immaterial.

We have cash till next August, don't forget.

Have SAR management told you why the MHRA have a GLP issue with that drug, btw? I am a Test Facility Manager of a GLP Facility, so I'm intrigued by that one. If that were VAL, there's no way the BOD wouldn't inform SHs, so that's why I'm more comfortable here.

I'd told shareholders that I'd try to get something on 201, George, as a SH rep., that could be relayed to everyone.

Due to Suzy NOT telling me anything and unable to do what I'd suggested, I told some of the more favourable posters (either here or on TG) that there was probably limited scope of the role, if a shareholder rep. couldn't gain leverage for more (public) information.

As it happens, I'm getting on very well now with Suzy, as the largest SH; don't have to convey duplicate emails to her about things that cannot be solved, and can focus on a higher-level conversation around RNS delivery etc. She's been very open to this, which I'm really encouraged by.

You can say I was bad at the SH role; couldn't deliver, or that VAL are overly-sensitive. Either way, it can be argued that the latter is probably better than a leaking ship, to coin your analogy. Suzy doesn't copy the wrong people into emails, for example.

Like a desperate peeper the the TG woods; silent, binoculars in hand, mouth open, and trousers down, you saw the headlights flash, fabricated some absurd story, and came on here to cause trouble.

The mole told everyone, rather unceremoniously, that it was a mole.

You're hubris in this schoolboy error was noted, you were booted, and we celebrated.

It's fairly sad, and you need to move on.

Good morning.

Tip top, thanks.

VAL is essentially a start up, but with a shadow (201), that curses it. If you can look past it, the rest is much better.

And even 201 won't go on forever.

Zai Ahmad is a very good appointment.

She worked in the same department as me, at a different time.

Naturally, I availed myself to contacting a couple of former colleagues, and they speak of her very highly. This is obviously good news.

At least now the Company have three scientists, instead of just one; so I would hope that news flow would be swifter from here on in, regarding, firstly CLX001.

Talking of which, they are testing the formulation now, which will be used for the regulatory development work (that's the bit I work in).

I know other Companies who would be singing and dancing over this, when complete, because it's no minor event. I've seen reformulation RNSs, in fact.

It's not all bad, and it's a shame to be in the low teens again, but that is the nature of AIM; the need for regular news flow (which I believe can be improved); and subsequent the building of market sentiment. I have chatted to Suzy about this today, and will be doing more frequently.

If there's a new patent for 301, it's basically a new drug.

We know that it is well-tolerated, from extrapolation from 201.

So if there's a new patent, the chances, in my view, of successfully getting it sold, are very high.

This could be the dark horse in the portfolio.

Funnily enough, I decided that re-duplicating various points brought up by shareholders, to the BOD, was a waste of both parties' time.

As a larger shareholder, it's better to now utilise my efforts to make general higher-level suggestions. I've made a number today, in fact.

The RNS had around 8 material pieces of work, which required a lot of effort. I liked that. I liked less that the Company had not taken individual credit for some of those developments, and a lot of potential had been somewhat lost with the Hokkaido delay.

Suzy in particular has been open to a dialogue with me over this. I feel more listened to as a larger retail older, and I'm happy to try to engage with the Company from this angle.

If I was unhappy, I'd have sold shares, but in fact I am going to have a wee top up, based on what I've read between the lines of that RNS.

The Hokkaido delay probably means that the Company are trying to re-jig the drug to make sure that, if it is tested, the results are robust and reliable. You have to be careful with peptide-like drugs, as they can sometimes act a bit squiffy, and so I know from this, that if it goes into an SPV, then the chances of success are particularly higher if they've got this right from the start.

There's actually an absolute plethora of work in there, on those preclinical assets.

It's been lost due to the Hokkaido delay, unfortunately, but that level of work is way beyond what the previous BOD could ever have accomplished in 1 year of evaluation.

And it looks to have been done properly.

Because 301 was evidently so monumentally not developed properly, they are re-patenting it, George.

That's not lost on me. Worth a delay on that, if they can achieve it.

The SP is disappointing, we agree on that, but in terms of pharmaceutical development, it's like comparing infants to a Professor, I have to be honest.

Well if they were, I'd wager they're not now.

And if they were, I'd question how many years would you retain an interest in the downfall of a failed job.

Sometimes you need be forced to move on, for your own good.

As far as I'm aware, the Telegram "cull" has removed a peeper, whom was using the channel as a means to try and degrade the Company. This was nothing to do with the current management.

In addition, a number of SP opportunists have gone with it.

I'm not admin, but I'm sure that genuine and identifiable SHs would always be welcome on there; especially if they were removed by accident.

The childish insults need to stop - it removes weight from voicing what may otherwise be a valid point.

I get that folk are annoyed with 201 and TX. I'd be lying if I said I wasn't fairly fed up myself. But I haven't sold a share, based on it.

Chin up.

There's one - and possibly up to three - world-class new compounds to look forward to.

Any one of these in an SPV is worth 10-15M.

If Suzy can deliver us two or three, and get a means of piggy-backing on momentum for the tCRO, to become sustainable, she would go to hero status.

I'd only say think on that for the next 6 weeks...see how you feel.

Have a good weekend all.

When any new SPVs are announced, I will be in florid correspondence.

I'm not privy to the inner workings of these, but I'm good with Google ;-)

I am alive and well, and I haven't sold a share fella.

As a biologist, did you know that a Gnat is nearly as tight as the available information surrounding TheoremRx's fundraise? Nearly as tight, but misses out by a few micrometers, in not being able to hold water.

They do use other treatments, but with very limited success. I think Suzy will design the preclinical trial both as a monotherapy, and in conjunction with some of these currently used compounds; particularly those that prime the natural immune system.

Nice one Novice x

I must admit, Suzy does actually now look like she's full of confidence and unconcerned, and I think I am too.

Nomlungo,

That's all good if your breast cancer has the HER2 receptor, but the target population of the new KC compound is specifically aimed at breast cancers that lack this receptor, plus the other two major ones (hence "triple negative"). That's why it's virtually impossible to currently treat.

It's a totally different therapy area, beyond just lumping "breast cancer".

I think IM was suggesting that compounds could be dropped before any deadline, but that results will naturally come in, over the months, before that deadline. That's not disseminated to SHs, as all info is needed before a go/no go decision.

I'd be very surprised if all three got to SPV stage, but that would be absolutely terrific.

In some ways, that relates to SAR (whom I wish well), because at 2.5 years in an SPV, at a comparable MCap, we'd be worth 300M if all completed the cycle, which would be about right, price-wise.

Basically, I'm happy to stick around for that :-).

As a toxicological pathologist myself, I always recommend doing it early! Suzy knows my thoughts! But I would expect it to start early, rather than leave it to year 2, like big pharma would.

Talking of big pharma, if they were capable of developing something like this (they are not), then they'd have spent about 20-30M plus to get something to this stage.

What got me salivating was that Martin spoke of a potential "series" of these drugs. So, even if '001 didn't progress, we have '002, 3, 4 etc as a possibility to take forward in the SPV, if both parties agreed, which I think they would.

I said yesterday that Martin probably couldn't believe his luck that there was a set up to turn his project into a drug, and Suzy probably couldn't believe her luck with this opportunity, so everyone is happy, including me :-)

It's better than good IMO. I'm assuming that VAL have recapitulated the early efficacy work. Some of the mice were completely cured, living for 200 days (equivalent to 20 years in humans). They may have stopped the experiment then; I.e they could have effectively lived for the full two years of a mouse lifespan (they tend to be developing spontaneous tumours by then).

If that were a group of 10 mice, and did the same, and the compound passes the toxicity testing in non-inmunocompromised (non tumour-bearing "healthy") animals, then even Dianne Abbott could sell that to big pharma.

01. If others wish to, go for it, but I personally think it's a waste of emotional energy,